LPBP Inc – ‘6-K’ for 2/3/03

On:  Monday, 2/3/03, at 11:55am ET   ·   For:  2/3/03   ·   Accession #:  909518-3-40   ·   File #:  0-31102

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Report of a Foreign Private Issuer   —   Form 6-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report of a Foreign Private Issuer                     5     13K 

6-K
1st Page of 5
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

 PURSUANT TO RULE 13A-16 OR 15D-16
OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2003                                                   

Hemosol Inc.
--------------------------------------------------------------------------------
 (Translation of registrant's name into English)

 2585 Meadowpine Boulevard, Mississauga, Ontario L5N 8H9
--------------------------------------------------------------------------------
 (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports 
under cover of Form 20-F or Form 40-F. Form 20-F [ ]   Form 40-F [X]            

Indicate by check mark whether the registrant by furnishing the information     
contained in this Form is also thereby furnishing the information to the        
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ]   No [X]                                                                

6-K
2nd Page of 5
TOC
1st
Previous
Next
↓Bottom
Just 2nd
The following are included in this Report on Form 6-K:                          

1. Press Release dated January 20, 2003.                                        

2. Press Release dated January 22, 2003.                                        

6-K
3rd Page of 5
TOC
1st
Previous
Next
↓Bottom
Just 3rd
Hemosol Announces CEO Undergoing Medical Treatment                              

TORONTO, ON, January 20, 2003 - Hemosol Inc. (NASDAQ: HMSL, TSX: HML, HML.WT)   
today announced that John Kennedy, the Company's President and Chief Executive  
Officer, is undergoing outpatient cancer treatment. Acting upon the advice and  
approval of his physicians, and with the support of the Board of Directors, Mr. 
Kennedy will continue in his role and responsibilities within the organization  
during therapy.                                                                 

"I have confidence in our ability to execute our plan and to maintain our       
momentum while I address this personal challenge. I will continue to be involved
in the ongoing operations of the Company during my treatment," said John        
Kennedy, Hemosol's President and CEO. "I expect a complete recovery and look    
forward to returning to my full time duties at Hemosol."                        

The incumbent management group will continue to implement the Company's business
strategy on a day to day basis. In addition to the ongoing validation of the    
Meadowpine facility, enrolment continues in Hemosol's two top priority clinical 
trials for HEMOLINK(TM) [hemoglobin raffimer]. The first of these, HLK 213, is  
an ongoing study of the safety and efficacy of using HEMOLINK in primary        
coronary artery bypass grafting (CABG) surgery and the second, HLK 210, is      
assessing the use of HEMOLINK in patients undergoing orthopedic surgery. The    
Company continues to expect to move forward to Phase III during 2003.           

"We wish John a quick return to good health and we expect that everyone will    
respect his right to personal privacy," said Edward Rygiel, Chairman of Hemosol.
"During this period, Hemosol's senior management team will work closely with    
John and myself to ensure that the direction set for the Company is implemented 
as planned."                                                                    

About Hemosol Inc. Hemosol is a near-term, commercial-stage biopharmaceutical   
company focused initially on developing life-sustaining therapies for the       
treatment of acute anemia. Hemosol has a broad range of products in development,
including its flagship product HEMOLINK(TM) [hemoglobin raffimer], an oxygen    
therapeutic, that is designed to rapidly and safely improve oxygen delivery via 
the circulatory system. HEMOLINK is currently being evaluated in late-stage     
clinical trials. The Company also is developing additional oxygen therapeutics  
and a hemoglobin-based drug delivery platform to treat diseases such as         
hepatitis C and cancers of the liver, as well as a cell therapy initially       
directed to the treatment of cancer through its cell expansion and stem cell    
research activities. Hemosol Inc.'s common shares are listed on The NASDAQ Stock
Market under the trading symbol "HMSL" and on the Toronto Stock Exchange under  
the trading symbol "HML". HEMOLINK is a registered trademark of Hemosol Inc.    

6-K
4th Page of 5
TOC
1st
Previous
Next
↓Bottom
Just 4th
Hemosol Appoints New Member to Board of Directors                               

TORONTO, ON, January 22, 2003 - Hemosol Inc. (NASDAQ: HMSL, TSX: HML, HML.WT)   
today announced that Edward E. McCormack has joined the Company's Board of      
Directors. Mr. McCormack was the Chief Financial Officer and a Director of      
Novopharm Limited from 1987 to 1999. Novopharm is one of North America's largest
generic pharmaceutical product manufacturers. While at Novopharm, he was also   
CFO of Novopharm Biotech Inc. (renamed Viventia Biotech Inc.), a company listed 
on the Toronto Stock Exchange. Mr. McCormack is currently President of Almad    
Investments Ltd. and Beaver Power Corporation. "The board will benefit greatly  
from Mr. McCormack's significant experience and insight into all aspects of     
financial and administrative management for public companies as well as from his
strong background in the pharmaceutical and biotech sectors," said Edward       
Rygiel, Chairman, Hemosol Inc. Mr. McCormack earned a Bachelor of Commerce      
degree from the University of Toronto and is a member of the Ontario Institute  
of Chartered Accountants. About Hemosol Inc. Hemosol is a near-term,            
commercial-stage biopharmaceutical company focused initially on developing      
life-sustaining therapies for the treatment of acute anemia. Hemosol has a broad
range of products in development, including its flagship product HEMOLINK(TM)   
[hemoglobin raffimer], an oxygen therapeutic, that is designed to rapidly and   
safely improve oxygen delivery via the circulatory system. HEMOLINK is currently
being evaluated in late-stage clinical trials. The Company also is developing   
additional oxygen therapeutics and a hemoglobin-based drug delivery platform to 
treat diseases such as hepatitis C and cancers of the liver, as well as a cell  
therapy initially directed to the treatment of cancer through its cell expansion
and stem cell research activities. Hemosol Inc.'s common shares are listed on   
The NASDAQ Stock Market under the trading symbol "HMSL" and on the Toronto Stock
Exchange under the trading symbol "HML". HEMOLINK is a registered trademark of  
Hemosol Inc. Certain statements concerning Hemosol's future prospects are       
"forward-looking statements" under the United States Private Securities         
Litigation Reform Act of 1995. There can be no assurances that future results   
will be achieved, and actual results could differ materially from forecasts and 
estimates. Important factors that could cause actual results to differ          
materially from forecasts and estimates include, but are not limited to:        
Hemosol's ability to obtain regulatory approvals for its products; Hemosol's    
ability to successfully complete clinical trials for its products; technical or 
manufacturing or distribution issues; the competitive environment for Hemosol's 
products; the degree of market penetration of Hemosol's products; and other     
factors set forth in filings with Canadian securities regulatory authorities and
the U.S. Securities and Exchange Commission. These risks and uncertainties, as  
well as others, are discussed in greater detail in the filings of Hemosol with  
Canadian securities regulatory authorities and the U.S. Securities and Exchange 
Commission. Hemosol makes no commitment to revise or update any forward-looking 
statements in order to reflect events or circumstances after the date any such  
statement is made.                                                              

6-K
Last Page of 5
TOC
1st
Previous
Next
↓Bottom
Just 5th
SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the    
undersigned, thereunto duly authorized.                                         

HEMOSOL INC.    

Date: February 3, 2003          By: /s/  Lee D. Hartwell                        
                                   -------------------------------------------
             Name: Lee D. Hartwell
                          Title: Chief Financial Officer and
                                          Vice-President Corporate Development

Dates Referenced Herein

				Referenced-On Page
This ‘6-K’ Filing		Date		First		Last			Other Filings
Filed on / For Period End:		2/3/03		5					None on these Dates
		1/22/03		2		4
		1/20/03		2		3
									List all Filings